1. Home
  2. TIL

as 11-15-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Founded: 2018 Country:
United States
United States
Employees: N/A City: DALLAS
Market Cap: 218.4M IPO Year: 2021
Target Price: $100.33 AVG Volume (30 days): 154.7K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -11.56 EPS Growth: N/A
52 Week Low/High: $6.08 - $92.00 Next Earning Date: 11-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 2.64%

TIL Daily Stock ML Predictions

Share on Social Networks: